Literature DB >> 33404860

Macrophages in multiple myeloma: key roles and therapeutic strategies.

Khatora S Opperman1,2, Kate Vandyke1,2, Peter J Psaltis3,4, Jacqueline E Noll5,6, Andrew C W Zannettino1,2,4.   

Abstract

Macrophages are a vital component of the tumour microenvironment and crucial mediators of tumour progression. In the last decade, significant strides have been made in understanding the crucial functional roles played by macrophages in the development of the plasma cell (PC) malignancy, multiple myeloma (MM). Whilst the interaction between MM PC and stromal cells within the bone marrow (BM) microenvironment has been extensively studied, we are only just starting to appreciate the multifaceted roles played by macrophages in disease progression. Accumulating evidence demonstrates that macrophage infiltration is associated with poor overall survival in MM. Indeed, macrophages influence numerous pathways critical for the initiation and progression of MM, including homing of malignant cells to BM, tumour cell growth and survival, drug resistance, angiogenesis and immune suppression. As such, therapeutic strategies aimed at targeting macrophages within the BM niche have promise in the clinical setting. This review will discuss the functions elicited by macrophages throughout different stages of MM and provide a comprehensive evaluation of potential macrophage-targeted therapies.

Entities:  

Keywords:  Macrophages; Microenvironment; Multiple myeloma; Therapeutics

Year:  2021        PMID: 33404860     DOI: 10.1007/s10555-020-09943-1

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  93 in total

1.  Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.

Authors:  Yazan Alsayed; Hai Ngo; Judith Runnels; Xavier Leleu; Ujjal K Singha; Costas M Pitsillides; Joel A Spencer; Teresa Kimlinger; Joanna M Ghobrial; Xiaoying Jia; Ganwei Lu; Michael Timm; Ashok Kumar; Daniel Côté; Israel Veilleux; Karen E Hedin; G David Roodman; Thomas E Witzig; Andrew L Kung; Teru Hideshima; Kenneth C Anderson; Charles P Lin; Irene M Ghobrial
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

Review 2.  Frontline therapy of multiple myeloma.

Authors:  Philippe Moreau; Michel Attal; Thierry Facon
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

3.  A niche-dependent myeloid transcriptome signature defines dormant myeloma cells.

Authors:  Weng Hua Khoo; Guy Ledergor; Assaf Weiner; Daniel L Roden; Rachael L Terry; Michelle M McDonald; Ryan C Chai; Kim De Veirman; Katie L Owen; Khatora S Opperman; Kate Vandyke; Justine R Clark; Anja Seckinger; Natasa Kovacic; Akira Nguyen; Sindhu T Mohanty; Jessica A Pettitt; Ya Xiao; Alexander P Corr; Christine Seeliger; Mark Novotny; Roger S Lasken; Tuan V Nguyen; Babatunde O Oyajobi; Dana Aftab; Alexander Swarbrick; Belinda Parker; Duncan R Hewett; Dirk Hose; Karin Vanderkerken; Andrew C W Zannettino; Ido Amit; Tri Giang Phan; Peter I Croucher
Journal:  Blood       Date:  2019-04-25       Impact factor: 22.113

4.  Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma.

Authors:  T Hideshima; N Nakamura; D Chauhan; K C Anderson
Journal:  Oncogene       Date:  2001-09-20       Impact factor: 9.867

5.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

Review 6.  Multiple myeloma.

Authors:  Shaji K Kumar; Vincent Rajkumar; Robert A Kyle; Mark van Duin; Pieter Sonneveld; María-Victoria Mateos; Francesca Gay; Kenneth C Anderson
Journal:  Nat Rev Dis Primers       Date:  2017-07-20       Impact factor: 52.329

7.  A monoclonal gammopathy precedes multiple myeloma in most patients.

Authors:  Brendan M Weiss; Jude Abadie; Pramvir Verma; Robin S Howard; W Michael Kuehl
Journal:  Blood       Date:  2009-02-20       Impact factor: 22.113

Review 8.  Pathogenesis of myeloma bone disease.

Authors:  G D Roodman
Journal:  Leukemia       Date:  2008-11-27       Impact factor: 11.528

9.  Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016.

Authors:  Andrew J Cowan; Christine Allen; Aleksandra Barac; Huda Basaleem; Isabela Bensenor; Maria Paula Curado; Kyle Foreman; Rahul Gupta; James Harvey; H Dean Hosgood; Mihajlo Jakovljevic; Yousef Khader; Shai Linn; Deepesh Lad; Lorenzo Mantovani; Vuong Minh Nong; Ali Mokdad; Mohsen Naghavi; Maarten Postma; Gholamreza Roshandel; Katya Shackelford; Mekonnen Sisay; Cuong Tat Nguyen; Tung Thanh Tran; Bach Tran Xuan; Kingsley Nnanna Ukwaja; Stein Emil Vollset; Elisabete Weiderpass; Edward N Libby; Christina Fitzmaurice
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777

10.  Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche.

Authors:  Michelle A Lawson; Michelle M McDonald; Natasa Kovacic; Weng Hua Khoo; Rachael L Terry; Jenny Down; Warren Kaplan; Julia Paton-Hough; Clair Fellows; Jessica A Pettitt; T Neil Dear; Els Van Valckenborgh; Paul A Baldock; Michael J Rogers; Colby L Eaton; Karin Vanderkerken; Allison R Pettit; Julian M W Quinn; Andrew C W Zannettino; Tri Giang Phan; Peter I Croucher
Journal:  Nat Commun       Date:  2015-12-03       Impact factor: 14.919

View more
  5 in total

1.  Integrative analysis identifies CXCL11 as an immune-related prognostic biomarker correlated with cell proliferation and immune infiltration in multiple myeloma microenvironment.

Authors:  Huizhong Wang; Ruonan Shao; Wenjian Liu; Shumei Peng; Shenrui Bai; Bibo Fu; Congling Zhao; Yue Lu
Journal:  Cancer Cell Int       Date:  2022-05-14       Impact factor: 6.429

Review 2.  Tumor-associated macrophages in multiple myeloma: advances in biology and therapy.

Authors:  Jennifer Sun; Chaelee Park; Nicole Guenthner; Shannon Gurley; Luna Zhang; Berit Lubben; Ola Adebayo; Hannah Bash; Yixuan Chen; Mina Maksimos; Barbara Muz; Abdel Kareem Azab
Journal:  J Immunother Cancer       Date:  2022-04       Impact factor: 12.469

Review 3.  The yin-yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma.

Authors:  Zhigang Yi; Tao Ma; Jia Liu; Wenting Tie; Yanhong Li; Jun Bai; Lijuan Li; Liansheng Zhang
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

4.  Immune microenvironment characteristics in multiple myeloma progression from transcriptome profiling.

Authors:  Jin Wang; Yi Hu; Habib Hamidi; Cedric Dos Santos; Jingyu Zhang; Elizabeth Punnoose; Wenjin Li
Journal:  Front Oncol       Date:  2022-08-12       Impact factor: 5.738

Review 5.  Reviewing the Significance of Vitamin D Substitution in Monoclonal Gammopathies.

Authors:  Vanessa Innao; Alessandro Allegra; Lia Ginaldi; Giovanni Pioggia; Massimo De Martinis; Caterina Musolino; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2021-05-06       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.